---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116005"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:31:38.139503+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Carisma Therapeutics reports Q3 2023 net loss of $21.4M; cash $94.1M funds into Q1 2025

## Summary
- Net loss of $21.4M for Q3 2023 vs. $18.3M for Q3 2022.
- Cash, cash equivalents and marketable securities of $94.1M as of Sept 30, 2023.
- R&D expenses $19.6M, up $4.0M YoY, driven by CT-0525 preclinical costs.
- Selected clinical candidate for CT-1119 (anti-mesothelin CAR-Monocyte); IND targeted for 2025.
- Updated Phase 1 data for CT-0508 shows safety and biomarker correlation with stable disease.

## SEC filing metadata
- accession: 0001104659-23-116005
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465923116005/0001104659-23-116005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465923116005/tm2330254d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116005
- JSON: https://secwatch.observer/filing/0001104659-23-116005.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116005.txt

## Key facts
- Earnings Releases
  Carisma Therapeutics Inc. reported the quarter ended September 30, 2023 results: net income Net loss was $21.4 million for the third quarter of 2023, compared to net loss of $18.3 million for the same period in 2.
  - Period: the quarter ended September 30, 2023
  - Net income: Net loss was $21.4 million for the third quarter of 2023, compared to net loss of $18.3 million for the same period in 2
  - Result: reported results
  source text: Carisma Therapeutics Inc. (the "Company") announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000110465923116005/0001104659-23-116005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.